Tolerability of [177Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.
Publication
, Conference
Tagawa, ST; Armstrong, AJ; Krause, BJ; Herrmann, K; Rahbar, K; De Bono, JS; Adra, N; Desilvio, M; Messmann, R; Holder, G; Chi, KN
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Tagawa, S. T., Armstrong, A. J., Krause, B. J., Herrmann, K., Rahbar, K., De Bono, J. S., … Chi, K. N. (2022). Tolerability of [177Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Tagawa, Scott T., Andrew J. Armstrong, Bernd J. Krause, Ken Herrmann, Kambiz Rahbar, Johann S. De Bono, Nabil Adra, et al. “Tolerability of [177Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Tagawa ST, Armstrong AJ, Krause BJ, Herrmann K, Rahbar K, De Bono JS, et al. Tolerability of [177Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.
Tagawa, Scott T., et al. “Tolerability of [177Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.
Tagawa ST, Armstrong AJ, Krause BJ, Herrmann K, Rahbar K, De Bono JS, Adra N, Desilvio M, Messmann R, Holder G, Chi KN. Tolerability of [177Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis. JOURNAL OF CLINICAL ONCOLOGY. 2022.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences